Rick Jantz

Associate
Full contact info

Experience

X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics

September 2, 2019

Cooley advised X4 Pharmaceuticals in its exclusive license agreement with Abbisko Therapeutics granting Abbisko exclusive rights to develop and commercialize maxorixafor in combination with checkpoint inhibitors or other agents in oncology indications in China, Taiwan, Hong Kong and Macau.

Related contacts

Geoffrey Spolyar
Partner, Boston
Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Los Angeles Santa Monica

Related Practices & Industries

GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals

September 2, 2019

Cooley advised GENFIT SA in its licensing and collaboration agreement with Terns Pharmaceuticals. Terns will have the rights to develop and commercialize elafibranor, GENFIT’s proprietary compound, in Greater China. Under the terms of the agreement, GENFIT received an upfront payment from Terns of $35 million and will be eligible to receive up to $193 million in potential clinical, regulatory and commercial milestone payments.

Related contacts

Geoffrey Spolyar
Partner, Boston
Christina Zhang
Partner, Shanghai
Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Los Angeles Santa Monica

Related Practices & Industries

Vir Biotechnology - $143 Million IPO

October 17, 2019

Cooley advised Vir Biotechnology on its $142.9 million initial public offering of 7,142,858 shares of common stock. Vir Biotechnology, whose securities now trade on Nasdaq Global Select Market under the symbol "VIR", is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Partners Laura Berezin, Charlie Kim and Kristin VanderPas led the Cooley team.

Related contacts

Laura Berezin
Partner, Seattle
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Sara Semnani
Partner, Los Angeles Santa Monica
Carlos Ramirez
Partner, San Diego
Chen Chen
Associate, Palo Alto
Sarah Choi
Associate, Los Angeles Santa Monica
Karen Tsai
Special Counsel, Washington, DC
Mary Maher Lewis
Special Counsel, Reston
Xander Lee
Partner, Los Angeles Santa Monica
Francis Wheeler
Partner, Colorado
Ivor Elrifi
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Rick Jantz
Associate, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Phil Mitchell
Partner, New York
Wendy Brenner
Partner, Palo Alto
Koji Fukumura
Partner, San Diego
Kate Hillier
Partner, Seattle
David Burns
Special Counsel, Washington, DC
Selin Akkan
Associate, Palo Alto

Related Practices & Industries

Arlo to Partner with Verisure

November 21, 2019

Cooley advised Arlo Technologies, the leading internet-connected camera brand, on its agreement to enter into a strategic partnership with Verisure Sàrl. Partners Barbara Borden, Tom Coll and Charles Haley led the Cooley team advising Arlo.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Tom Coll
Partner, San Diego
Charles Haley
Partner, Palo Alto
Xander Lee
Partner, Los Angeles Santa Monica
Howard Morse
Partner, Washington, DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Paula Holland
Partner, London
David Navetta
Partner, Colorado
Chris Coulter
Partner, London
John Paul Oleksiuk
Partner, New York
Lesse Castleberry
Senior Counsel, New York
Thomas Welk
Senior Counsel, San Diego
Michael Klein
Partner, New York
Stella Sarma
Special Counsel, Brussels
Chris Chynoweth
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Lindsey O'Crump
Associate, Washington, DC
Megan Browdie
Partner, Washington, DC
Jan Lang
Associate, Brussels
Dionne A. Thomas
Associate, San Diego
Chris Stack
Partner, London
Russell Anderson
Associate, London

Related Practices & Industries

Reata Pharmaceuticals – $505 Million Follow-On Offering

December 9, 2019

Cooley advised the underwriters on Reata Pharmaceuticals' $505 million follow-on offering of 2,760,000 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Cantor, Baird and Ladenburg Thalmann acted as co-managers for the offering. Partners Rich Segal, Div Gupta and Charlie Kim led the Cooley team.

Read more

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Charlie Kim
Partner, San Diego
Asher Herzog
Associate, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Jennifer Shanley
Special Counsel, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Kenneth Krisko
Partner, Reston
William Corcoran
Of Counsel, Boston
Stephanie Gentile
Partner, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Rebecca Ross
Special Counsel, Washington, DC
Francis Wheeler
Partner, Colorado

Related Practices & Industries

View more